Novartis AG has synthesized heteroaryl aminopropanol derivatives acting as leukotriene A4 hydrolase (LTA4H; LTA4) inhibitors reported to be useful for the treatment of cancer, chronic obstructive pulmonary disease (COPD), psoriasis, sepsis, periodontal and autoimmune disease, cardiovascular and inflammatory disorders, among others.